Drug
Elenbecestat clinical trials
Also written E2609.
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 4 |
| 2016 | 2 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Itraconazole (1) · Rifampin (1) · Digoxin (1) · Donepezil (1)
Studies
Open first, then newest update. How each study uses elenbecestat is read from its arms, and is right about nine times in ten.
Testing it · 12
- Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's DiseaseTerminatedPhase 2Eisai Inc.NCT02322021Written as E2609
- A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's DiseaseTerminatedPhase 3Eisai Co., Ltd.NCT02956486Written as Elenbecestat
- A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy SubjectsCompletedPhase 1Eisai Inc.NCT02859207Written as E2609
- Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese SubjectsCompletedPhase 1Eisai Co., Ltd.NCT03055962Written as E2609
- Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)CompletedPhase 1Eisai Inc.NCT01600859Written as E2609
- An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male SubjectsCompletedPhase 1Eisai Inc.NCT01975636Written as E2609
- A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy SubjectsCompletedPhase 1Eisai Inc.NCT02222324Written as E2609
- A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or DonepezilCompletedPhase 1Eisai Inc.NCT02055703Written as E2609
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White SubjectsCompletedPhase 1Eisai Inc.NCT02207790Written as E2609
- Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy SubjectsCompletedPhase 1Eisai Inc.NCT01511783Written as E2609
- Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly CohortCompletedPhase 1Eisai Inc.NCT01294540Written as Drug: E2609
- An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on AbsorptionCompletedPhase 1Eisai Inc.NCT01716897Written as E2609
Codes
What other systems call elenbecestat · ClinicalTrials.gg INT017829
- UNII (FDA) RXJ96XL94HELENBECESTATConfirmed FDA, Wikidata
- Wikidata Q106637617elenbecestatConfirmed FDA, Wikidata
- NCI Thesaurus C169934ElenbecestatOne source FDA
- DrugBank DB15391One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | RXJ96XL94H | ELENBECESTAT | Confirmed FDA, Wikidata |
| Wikidata | Q106637617 | elenbecestat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C169934 | Elenbecestat | One source FDA |
| DrugBank | DB15391 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.